In the current study, we found that blocking CCR2 not only abrogated the beneficial effect of PD-L1 immunotherapy on cognitive performance, local brain inflammation, and pathological manifestations, but also prevented the accumulation of Tregs in the diseased brain. This evidence concerns the gene CD274 and inflammatory response.